The leading trade group lobbying for the US pharma industry has released a new analysis pinning the blame for high drug prices on so-called middlemen in the healthcare sector.
The release of the report coincides with potentially negative media coverage, with congressional hearings taking place on Tuesday, in which chief executives from six of the world’s largest drugmakers face questions from senators over high prices.
The pharma industry has long blamed pharmacy benefit managers (PBM) and other intermediaries for high prices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze